Neuroblastoma tumor-associated antigens

Neuroblastoma tumor-associated antigens (TAAs) refer to a heterogeneous group of proteins overexpressed on neuroblastoma cells, including tyrosine hydroxylase (TH), PHOX2B, glypican-2 (GPC2), B7-H3 (CD276), Survivin (BIRC5), and cancer-testis antigens like PRAME, MAGEA1, MAGEA3, and NY-ESO-1. These antigens are highly expressed in most neuroblastoma tumors, enabling distinction from benign tumors, and serve as markers for minimal residual disease monitoring, with specific patterns linked to prognosis—high TH, PHOX2B, and MAGEA1 indicate favorable outcomes, while high Survivin predicts relapse. Biologically, they support tumor survival through roles in catecholamine synthesis (TH), neural differentiation (PHOX2B), cell surface adhesion (GPC2), immune inhibition (B7-H3), apoptosis resistance (Survivin), and aberrant germ-cell-like expression (CTAs). In disease, they drive neuroblastoma progression, particularly in high-risk subtypes like MYCN-amplified or adrenergic (ADRN) tumors, though expression varies by ADRN vs. mesenchymal (MES) states, with B7-H3 and L1CAM showing pan-subtype consistency. Therapeutically, they are prime targets for immunotherapies including monoclonal antibodies, CAR-T cells, and vaccines, building on GD2-directed dinutuximab success, but challenges include expression heterogeneity, subtype specificity, and toxicity from normal tissue overlap. Overall, these TAAs highlight neuroblastoma's immunogenicity potential but underscore the need for multi-antigen strategies to address tumor plasticity and immune evasion.

Other names

tumor-specific antigensTAAscancer-testis antigens (CTAs)neuroblastoma antigens

Monoclonal antibodies (e.g., for B7-H3, GPC2; antibody-dependent cellular cytotoxicity); CAR-T cell therapy (e.g., for surface antigens like GPC2, B7-H3); Cancer vaccines (peptide, protein, RNA/DNA for CTAs like MAGEA3, NY-ESO-1, PRAME, Survivin); Small molecule inhibitors (e.g., for Survivin); Immunoconjugates (e.g., for AXL in MES subtype)